Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking the role of synergy calculations in the next century of drug combination discovery.

Med (New York, N.Y.)ยท2026
Same author

Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes.

Cell reports. Medicineยท2026
Same author

CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.

Oncotargetยท2026
Same author

Novel Mixed Cancer-Cell Models Designed to Capture Inter-Patient Tumor Heterogeneity for Accurate Evaluation of Drug Combinations.

International journal of molecular sciencesยท2026
Same author

Combined XPO1 Inhibition and Parthenolide Treatment Can Be Efficacious in Treating Triple-Negative Breast Cancer.

International journal of molecular sciencesยท2025
Same author

Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profiles.

bioRxiv : the preprint server for biologyยท2025
Same journal

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.

Future oncology (London, England)ยท2026
Same journal

Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).

Future oncology (London, England)ยท2026
Same journal

Plain language summary of the MiroCIP study: how often chemotherapy-induced peripheral neuropathy happens in the first year of oxaliplatin- or taxane-based chemotherapy.

Future oncology (London, England)ยท2026
Same journal

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)ยท2026
Same journal

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Future oncology (London, England)ยท2026
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)ยท2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Next-generation sequencing for lung cancer.

Kehua Wu1, R Stephanie Huang, Larry House

  • 1Department of Medicine, University of Chicago, Chicago, IL, USA.

Future Oncology (London, England)
|August 29, 2013
PubMed
Summary
This summary is machine-generated.

Next-generation sequencing (NGS) revolutionizes lung cancer research by enabling comprehensive genomic analysis. This technology enhances personalized medicine by identifying new mutations and refining understanding of known targets like EGFR, ALK, and KRAS.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Area of Science:

  • Oncology
  • Genomics
  • Biotechnology

Background:

  • Lung cancer is a leading cause of cancer deaths, with unique patient-specific characteristics.
  • Traditional Sanger sequencing is being superseded by more advanced methods for genetic analysis.
  • Personalized medicine requires a comprehensive understanding of the cancer genome.

Purpose of the Study:

  • To review next-generation sequencing (NGS) technologies and their applications in lung cancer research.
  • To summarize key findings from NGS in understanding lung cancer biology and treatment.
  • To highlight the role of NGS in advancing personalized lung cancer care.

Main Methods:

  • Review of current literature on next-generation sequencing (NGS) technologies.
  • Analysis of NGS applications in identifying genetic alterations in lung cancer.
  • Summary of findings from large-scale cancer genome studies.

Main Results:

  • NGS offers higher throughput and lower costs compared to traditional sequencing methods.
  • NGS has led to the discovery of additional lung cancer mutations beyond known targets (EGFR, ALK, KRAS).
  • NGS facilitates a global approach to cancer genome studies, advancing personalized medicine.

Conclusions:

  • NGS technologies are transforming lung cancer research and clinical practice.
  • Comprehensive genomic interpretation through NGS is crucial for personalized lung cancer treatment.
  • Continued advancements in NGS will further unravel the complexities of lung cancer.